Moderna Q1 loss smaller than expected as COVID vaccine sales rise

Moderna

01/05/2026 11:39

Overview

mRNA medicines developer's Q1 revenue rose sharply, beating analyst expectations

Q1 adjusted EPS beat analyst expectations despite a $0.9 bln litigation settlement charge

Company reiterated plan for up to 10% revenue growth and cost reductions in 2026

Outlook

Moderna targets up to 10% revenue growth for 2026 compared to 2025

Company expects 2026 revenue split to be about 50% U.S. and 50% international

Moderna projects year-end 2026 cash and investments at $4.5-$5.0 bln

Result Drivers

INTERNATIONAL COVID VACCINE SALES - Co said higher COVID vaccine sales in international markets, driven by deliveries under long-term strategic partnerships, boosted Q1 revenue

PRODUCT APPROVALS - Co cited new product approvals in Europe, including the flu plus COVID combination vaccine, as contributing to business momentum

LITIGATION SETTLEMENT CHARGE - Q1 results were negatively affected by a $0.9 bln non-recurring litigation settlement charge

Company press release: ID:nACSKxt5Ca

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
$389mln
$227.97 mln (13 Analysts)
Q1 EPS
Beat
-$3.40
-$3.96 (14 Analysts)
Q1 Net Income
-$1.34 bln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 4 "strong buy" or "buy", 17 "hold" and 3 "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Moderna Inc is $42.00, about 8.6% below its April 30 closing price of $45.94

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)